TickerFacts.

Company research / KNSA

Kiniksa Pharmaceuticals International, plc (KNSA)

Build a valuation ↗↓ Download CSV

CIK 0001730430 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M. Revenue grew 60.1% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $754.04M.

Key ratios (year ended 2025-12-31)

88.5%
Gross margin (computed)
11.4%
Operating margin
8.7%
Net margin
10.4%
Return on year-end equity
60.1%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-22

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-03-31		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$754.04M$677.56M$423.24M$270.26M$220.18M$38.54Mn/an/an/an/a
Cost of Revenue$80.60M$77.67M$60.91M$33.41M$22.89M$9.10Mn/an/an/an/a
Gross Profit (computed)$673.44M$599.89M$362.33M$236.85M$197.28M$29.44Mn/an/an/an/a
R&D Expense$105.00M$96.85M$111.62M$76.10M$65.49M$99.30M$112.04M$135.00M$86.60M$56.36M
Operating Income$93.22M$77.22M-$45.62M-$25.20M$9.77M-$156.64M-$157.36M-$169.96M-$108.16M-$65.40M
Depreciation & Amortization$1.68M$1.55M$1.70M$2.34M$2.40M$2.35M$2.40M$2.07Mn/an/a
EBITDA$94.89M$78.78M-$43.92M-$22.86M$12.18M-$154.28M-$154.96M-$167.90Mn/an/a
Net Income$73.06M$59.01M-$43.19M$14.08M$183.36M-$157.92M-$161.38M-$161.87M-$103.23M-$64.87M
EPS (Diluted)n/a$0.75-$0.60$0.20$2.60-$2.30-$2.61-$2.99n/an/a
Total Assets$825.28M$763.63M$580.55M$526.32M$459.67M$232.80M$349.46M$254.53M$321.96M$47.49M
Total Liabilities$219.59M$196.03M$142.12M$87.48M$63.52M$47.76M$37.53M$29.11M$42.70M$17.43M
Shareholders' Equity$605.69M$567.61M$438.44M$438.84M$396.15M$185.04M$311.94M$225.42M$279.27M-$89.71M
Cash & Equivalents$189.95M$165.60M$183.58M$107.95M$122.72M$122.47M$114.04M$46.93M$71.98M$45.55M
Operating Cash Flow$165.86M$137.99M$25.69M$13.30M$5.81M-$126.30M-$136.53M-$158.37M-$81.01M-$50.22M
Capital Expenditures$1.63M$1.57M$277.0K$130.0K$105.0K$415.0K$283.0K$3.20M$5.29M$69.0K
Free Cash Flow$164.23M$136.42M$25.41M$13.17M$5.70M-$126.71M-$136.81M-$161.57M-$86.30M-$50.29M
Dividends Paidn/an/an/an/an/an/an/an/a$0$0
Weighted Average Diluted Sharesn/a78.98M71.42M71.92M70.42M68.58M61.84M54.05Mn/an/a
EPS (Basic)n/a$0.80-$0.60$0.20$2.64-$2.30-$2.61-$2.99n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView